Business Information
The group's principal activity is to develop and manufacture recombinant antibodies and other protein products to treat cancer, immunological and inflammatory disorders and infectious diseases. The group's products are presently in various stages of development and all are subject to regulatory approval before the group or its collaborators can commercially introduce any products. Current strategic alliances of the group include baxter healthcare corporation, genentech inc., millennium pharmaceuticals, inc. And onyx pharmaceuticals, inc.
|
|
Name |
Title
|
Email
|
| John Castello | Chmn., CEO, Pres. | N/A | | David Boyle | CFO, VP - Finance | N/A | | Calvin McGoogan | VP - Quality, Facilities | N/A | | Charles Wells | VP - Human Resources, Information Technology | N/A | | Daniel Cafaro | VP - Regulatory Affairs, Compliance | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 29,498 | (51,841) | | 2005 | 18,669 | 2,779 | | 2004 | 3,665 | (78,942)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
